Telepsychiatry and anxiety care

Before 2020, telehealth was a small share of outpatient care and a smaller share of psychiatric care. During the pandemic, Medicare and most commercial payers loosened the rules, and psychiatric telehealth claims rose more than five-fold in a matter of months. Behavioral health has since held the highest telehealth share of any specialty. KFF's analysis of Medicare claims and Mehrotra and colleagues' analyses of commercial claims both find that behavioral-health visits remain about one-third telehealth years after the initial policy relaxation, a level no other specialty has come close to. See the network's evidence summary on telepsychiatry for anxiety for the clinical-outcome side of this same question.

The outcomes literature is now large enough to draw stable conclusions for the common cases. Hilty and colleagues' 2013 review, and Bashshur and colleagues' 2016 update, both concluded that telepsychiatry is generally comparable to in-person care for assessment, diagnosis, medication management, and CBT, with satisfaction levels among patients that match or exceed those of in-person care. More recent meta-analyses of telehealth-delivered CBT for anxiety and depression report effect sizes similar to those of face-to-face delivery.

The evidence is strongest for depression and anxiety, weaker for severe mental illness, and mixed for children, where family and school context can matter to the visit. Group therapies and modalities that involve physical interaction are the least well-studied in a telehealth format.

Telepsychiatry has produced the largest access gains where the in-person option was thinnest. HRSA-designated mental health professional shortage areas cover most rural US counties; telepsychiatry allows a patient in a shortage area to see a licensed psychiatrist who lives elsewhere in the same state. For a national picture of that geography, see the report on rural and urban access. Correctional systems, community mental health centers, and federally qualified health centers have used tele-consultation for the same reason.

Two federal frameworks shape what telepsychiatrists can and can't do. The first is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which requires an in-person medical evaluation before a controlled substance is prescribed by telemedicine, unless an exception applies. Pandemic-era waivers made most controlled-substance telehealth prescribing possible without an in-person visit, and the DEA has extended those flexibilities through a series of temporary rules while it works on a permanent framework. The rules for stimulants, benzodiazepines, and buprenorphine remain the most closely watched.

The second is state medical licensure. Physicians must be licensed in the state where the patient is located at the time of the visit. The Interstate Medical Licensure Compact has made it faster to hold multiple state licenses, but it doesn't waive the requirement. Some states have telehealth-specific registration or waivers; most don't. Payer coverage of audio-only visits, cross-state care, and originating-site rules varies by insurer and by state.

Telepsychiatry expands access; it doesn't create new prescribers. In a shortage area, tele-visits still draw on the national workforce of licensed psychiatrists, which itself is limited and unevenly distributed. Broadband access, device access, and comfort with technology are not universal, and they are correlated with income, age, and geography, which means telepsychiatry can widen access without closing all of the same gaps.

For patients whose situation includes psychiatric emergency, imminent risk of harm, medication-assisted treatment for opioid use disorder, or long-acting injectable medications, in-person care remains necessary at some point in the care plan.

The utilization data measure claims; they don't tell you whether the patient got well. The outcomes data measure averages across trials; they don't predict any one person's course. "Comparable outcomes" is a comparison, not a claim that telepsychiatry is preferable in every situation. Long-term outcomes and safety data for controlled-substance prescribing by telemedicine are still accumulating.

Telepsychiatry moved from a niche service to a mainstream mode of care between 2020 and the years that followed. Pandemic-era policy changes temporarily relaxed restrictions on telehealth, and use rose sharply. Mental health was the specialty where telehealth use stayed highest after the initial surge. Utilization data from CMS and SAMHSA show that a substantial share of outpatient psychiatric visits continued to be delivered virtually well after in-person care resumed, and behavioral health has consistently led all specialties in telehealth's share of visits.

The research on outcomes is reassuring. Systematic reviews report that telepsychiatry produces results broadly comparable to in-person care for assessment, medication management, and several psychotherapies, with high patient satisfaction. The access gains have been largest in rural and shortage areas, where telepsychiatry can connect a patient to a clinician who isn't physically nearby. Randomized trials of telehealth-delivered CBT for anxiety report effect sizes similar to face-to-face delivery.

The open questions are regulatory rather than clinical. The prescribing of controlled substances by telemedicine, governed by the federal Ryan Haight Act and by DEA rulemaking, has moved through a series of temporary extensions, and the long-term rules are still being worked out. State licensure remains a constraint, since a clinician must be licensed where the patient is located at the time of the visit. Payer coverage of audio-only visits, cross-state waivers, and originating-site rules vary by insurer and year.

Telehealth utilization shifts with policy. Figures from the pandemic peak aren't a steady-state baseline, and any current share should be read against the policy environment of its year.

"Comparable outcomes" in the outcomes literature means the average result is similar, not that telepsychiatry is right for every patient or every clinical situation.